Latvija -
latviešu -
Zāļu valsts aģentūra
hyoscine butylbromide kalceks 20 mg/ml šķīdums injekcijām
kalceks, a/s, latvia - hioscīna butilbromīds - Šķīdums injekcijām - 20 mg/ml
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
bridion
merck sharp & dohme b.v. - sugammadex - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - rokuronija vai vekuronija izraisītas neiromuskulārās blokādes atsākšana. par peadiatric iedzīvotāju skaits: sugammadex ir tikai ieteicama regulāra maiņa rocuronium izraisītu blokādes bērniem un pusaudžiem.
Latvija -
latviešu -
Zāļu valsts aģentūra
rocuronium bromide kalceks 10 mg/ml šķīdums injekcijām/infūzijām
kalceks, a/s, latvia - rokuronija bromīds - Šķīdums injekcijām/infūzijām - 10 mg/ml
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
sugammadex amomed
aop orphan pharmaceuticals gmbh - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - rokuronija vai vekuronija izraisītas neiromuskulārās blokādes atsākšana. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
sugammadex mylan
mylan ireland limited - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - talidomīds - multiple mieloma - imūnsupresanti - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
sugammadex fresenius kabi
fresenius kabi deutschland gmbh - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
thalidomide lipomed
lipomed gmbh - talidomīds - multiple mieloma - imūnsupresanti - thalidomide lipomed in combination with melphalan and prednisone is indicated as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. thalidomide lipomed is prescribed and dispensed in accordance with the thalidomide lipomed pregnancy prevention programme (see section 4.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
sugammadex piramal
piramal critical care b.v. - sugammadex sodium - neiromuskulārā blokāde - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
sugammadex adroiq
extrovis eu ltd. - sugammadex sodium - neiromuskulārā blokāde - visi pārējie terapeitiskie produkti - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.